Peptide therapy TikTok claims: hype vs. actual evidence

What did @fidelis.wellness actually say?

Christina, a nurse practitioner at Fidelis Wellness, was answering a viewer question about whether sermorelin and tesamorelin are the same thing. Her short answer: they work similarly but aren't equivalent. Both peptides stimulate the pituitary gland to release growth hormone, she said, but tesamorelin is "more potent" and better for "toning muscle," visceral fat loss, insulin sensitivity, and fatty liver improvement. Sermorelin, in her framing, is the milder option, better suited for sleep and hair, skin, and nails. She also recommended AOD-9604 over sermorelin for people specifically chasing visceral fat loss, especially if they're already on a GLP-1 medication.

The video is short and conversational, which means it glosses over some important distinctions. That's worth examining closely.

Does the science back this up?

Partially. The tesamorelin evidence is actually reasonably solid in one specific population. The rest gets shakier fast.

Tesamorelin is FDA-approved under the brand name Egrifta for HIV-associated lipodystrophy, and the clinical trial data supporting that indication is real. A 2010 randomized controlled trial by Falutz et al. published in the New England Journal of Medicine showed significant visceral adipose tissue reduction in HIV patients receiving tesamorelin versus placebo. Insulin sensitivity and lipid improvements were secondary findings in that same trial. So the visceral fat claim isn't invented.

Sermorelin is a truncated form of growth hormone-releasing hormone (GHRH). It has been studied, but the evidence base is much thinner and mostly older. A 1997 study by Vittone et al. in Metabolism found modest improvements in sleep quality and body composition with sermorelin in older adults, which loosely supports the sleep and body composition claims. But "hair, skin, and nails" as a primary benefit? That's marketing language more than a clinical finding.

AOD-9604 has almost no rigorous human trial data at this point. The Christina's recommendation to use it over sermorelin for visceral fat loss is not backed by published clinical evidence in humans.

What did they get wrong (or right)?

Credit where it's due: framing tesamorelin as more potent for visceral fat loss is directionally correct, and it's fair to note that the two peptides aren't interchangeable. That's a more honest comparison than a lot of peptide content on TikTok.

But there are real problems here. First, the claim that sermorelin helps with "hair, skin and nails" is not supported by controlled clinical trials. Growth hormone has downstream effects on IGF-1 which influences skin collagen, but jumping from that mechanism to a cosmetic benefit claim is a big leap with no solid study behind it.

Second, recommending AOD-9604 over sermorelin for visceral fat loss is irresponsible given the current evidence. AOD-9604 failed its Phase 3 clinical trials for obesity (Metabolic Pharmaceuticals, 2007), and it has not been approved for any indication. The FDA has also issued warning letters related to compounded AOD-9604. Presenting it as a reasonable clinical choice for someone on a GLP-1 medication, without any of that context, is misleading.

Third, the "fatty liver" improvement claim for tesamorelin is real but narrow. A 2018 study by Stanley et al. in Lancet HIV found liver fat reductions in HIV patients, not the general population seeking body recomposition.

What should you actually know?

If you're considering either of these peptides, the regulatory and evidence context matters more than a TikTok comparison.

Tesamorelin (Egrifta) is the only FDA-approved GHRH analog in the US, and its approval is narrow. Outside of HIV-associated lipodystrophy, its use is off-label, and compounded versions are not the same product as the approved drug. Sermorelin was FDA-approved but was voluntarily withdrawn from the US market by its original manufacturer. It now exists primarily as a compounded peptide, which means manufacturing quality and dosing consistency vary by pharmacy.

Both peptides work by stimulating your own pituitary to release growth hormone rather than injecting exogenous GH directly. That mechanism is genuinely different from synthetic HGH and is one reason some clinicians prefer them. But that distinction doesn't make the evidence base for off-label use any stronger.

Anyone seeing these peptides recommended on social media should ask their provider for the actual clinical rationale, not a TikTok comparison. And AOD-9604 specifically deserves a hard conversation before anyone considers it.